Online access to provider guided wellness programs
REJUVONIX
Checking session…
Menu

Protocol education · Cognitive / neurological

NAD+

NAD+ protocol education related to cellular-energy and wellness discussions.

Compounded medication vial
01

Understand

What this entry means.

This page provides structured education and a path to independent clinical review. Inclusion in the master protocol library is not a prescription, endorsement, guarantee of availability or statement that the protocol is appropriate for a particular person.

02

Discuss

What a provider may need to review.

  • Goal and symptoms prompting interest
  • Route, formulation and evidence considerations
  • Potential risks and alternatives
03

Verify

Regulatory and clinical context.

Evidence and regulatory considerations vary by formulation and route. Provider review is required when a prescription or compounded product is involved.

Connected pathway

From discovery to documented next steps.

Rejuvonix keeps the protocol pathway connected without bypassing provider review.

  1. 01Learn

    Review the protocol education and its regulatory context.

  2. 02Assess

    Complete the appropriate Rejuvonix assessment when you are ready.

  3. 03Provider review

    An independent licensed provider determines whether any treatment is appropriate.

  4. 04Source & document

    If treatment is prescribed, pharmacy/source and applicable quality documentation remain connected to the pathway.

Quality & documentation

Documentation follows the exact formulation and batch.

COAs shown here are the supplied documents for the named formulation and lot. Original certificate files are preserved unchanged. FDA-approved finished products use official prescribing documentation; compounded formulations may also have their own batch-specific COAs.

COA available

NAD+

Batch-by-batch COAs

Review the certificate package for each listed batch.

Some batches include more than one companion record. Part 1 and Part 2 links stay grouped under the same lot so the complete documentation set remains intact.

01

NAD+ batch

NAD+ 500 mg · 200 mg/mL solution

Lot / Batch
0059-070226-1
Laboratory
Miraxis Labs
Document date
2026-07-13

Next step

Clinical decisions stay with licensed providers.

Completing an assessment does not guarantee treatment or a prescription.

Continue to performance assessment